Catalog Number 02K45-28 |
Device Problem
High Test Results (2457)
|
Patient Problem
No Consequences Or Impact To Patient (2199)
|
Event Date 01/06/2016 |
Event Type
malfunction
|
Manufacturer Narrative
|
This issue was previously reported under mdr number 3002809144-2016-00005 under a different manufacturing site.Upon retrospective review, it was discovered that the manufacturing site of (b)(4).As reported in mdr number 3002809144-2016-00005 was incorrect.This mdr is to correct the manufacturing site to (b)(4), u.S.A.(b)(4).Review of the ticket trending and lot search did not identify an increase complaint activity related to falsely elevated results.Accuracy testing was completed using retained kits of reagent lot 50278m500.Acceptance criteria were met, which indicates acceptable product performance.Labeling was reviewed and adequately addresses the issue under review.Additionally, during troubleshooting, the customer observed the reagent bottles, noting that the microparticle bottle had slimy particles that didn't dissolve.The architect ca 125 ii package insert states to visually inspect the bottle to ensure microparticles have been completely resuspended and not use if the microparticles do not resuspend.A deficiency was not identified as panel testing shows that the likely cause lot performed per specification.There is not enough information to reasonably suggest a malfunction as the falsely elevated results gave the expected results when tested with a different kit of the same reagent lot.This indicates a possible issue with the initial reagent kit (microparticles bottle issue).The architect cea assay is performing acceptably.
|
|
Event Description
|
The account generated false elevated architect ca125 ii results on 4 patient samples that repeated in normal range after replacing the reagent.Patient 1 (female, (b)(6)) tested architect ca125 ii of 52.2, 46.7, 37.2 but repeated 13.7 after replacement reagent (no unit of measurement provided).Patient 2 (female, (b)(6)) tested architect ca125 ii of 39.9, 49.8, 51.1 but repeated 14 after replacement reagent.Patient 3 (female, (b)(6)) tested architect ca125 ii of 30.8 but repeated 7 after replacement reagent.Patient 4 (female, (b)(6)) tested architect ca125 ii of 51.5 but repeated 8.9 after replacement reagent.
|
|
Manufacturer Narrative
|
The device evaluation was reassessed and concluded that a malfunction occurred, therefore, the device was not performing as intended at the customer site.However, no systemic issue and/or product deficiency was identified.The conclusion code in evaluation codes was changed from (b)(4).
|
|
Search Alerts/Recalls
|
|